fulltext.pdf 180 KB
Watanabe, Kenta Department of Radiology, Okayama University Medical School
Nagao, Ryota Department of Radiology, Okayama University Medical School
Otsuki, Kaho Department of Radiology, Okayama University Medical School
Hiraki, Takao Department of Radiology, Okayama University Medical School Kaken ID publons researchmap
Breast cancer (BCa) frequently metastasizes to the bone. BCa patients with oligometastatic bone diseases have much more favorable outcomes than those with metastatic bone disease. Radiation therapy (RT), especially stereotactic body radiation therapy (SBRT), is advised for the treatment of patients with oligometastatic bone disease in other primary sites. "This line of treatment provided favorable outcomes in patients and resulted in only mild toxicities. A similar strategy has been suggested for treatment of BCa patients with oligometastatic bone disease. BCa, bone-only, or high radiation dose are reported to have been associated with good outcomes in RT for metastatic disease. Furthermore, based on the guidelines provided by the BCa expert panel of the German Society for Radiation Oncology and members of the Working Party of Gynecologic Oncology Breast Committee and in line of the results obtained in other primary sites, our group supports the use of high-dose RT or SBRT for the treatment of BCa patients with oligometastatic bone disease. Additionally, the use of magnetic resonance imaging (MRI) for proper target volume definition and three-dimensional (3D) treatment planning especially for lesions of the trunk are essential for the treatment planning of RT. Of note, several clinical trials have combined RT with immune checkpoint inhibitors for the treatment of BCa patients with metastatic disease. Based on this, we anticipate that combined RT and ICI may serve as a better treatment modality for BCa patients with oligometastatic bone disease.
breast cancer (BCa)
radiation therapy (RT)
stereotactic body radiation therapy (SBRT)
Translational Cancer Research
AME Publoshing Company
© Translational Cancer Research. All rights reserved.
|Web of Science KeyUT|